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Relationships between the rate of bone resorption (measured by urinary N-telopeptide (Ntx) excretion) and a range of skeletal
complications have been evaluated in patients with metastatic bone disease. A total of 121 patients had monthly measurements of
Ntx during treatment with bisphosphonates. All skeletal-related events, plus hospital admissions for bone pain and death during the
period of observation, were recorded. Data were available for 121 patients over the first 3-month period of monitoring (0–3
months) and 95 patients over the second 3-month period (4–6 months). N-telopeptide levels were correlated with the number of
skeletal-related events and/or death (r¼0.62, Po0.001 for 0–3 months and r¼0.46, Po0.001 for 4–6 months, respectively).
Patients with baseline Ntx values X100nmolmmol
 1 creatinine (representing clearly accelerated bone resorption) were 19.48
times (95% CI 7.55, 50.22) more likely to experience a skeletal-related event/death during the first 3 months than those with Ntx
o100 (Po0.001). In a multivariate logistic regression model, Ntx was highly predictive for events/death. This study is the first to
indicate a strong correlation between the rate of bone resorption and the frequency of skeletal complications in metastatic bone
disease. N-telopeptide appears useful in the prediction of patients most likely to experience skeletal complications and thus benefit
from bisphosphonate treatment.
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Metastatic bone disease presents a major challenge in the
management of several common cancers. Tumours of the breast
and prostate are particularly likely to metastasise to bone, with up
to 70% of patients dying with advanced metastatic disease showing
evidence of skeletal involvement at post mortem (Rubens, 2000).
Skeletal complications include hypercalcaemia, bone pain requir-
ing radiotherapy, pathological fracture and spinal cord or nerve
root compression. Additionally, a proportion of patients will die as
a direct consequence of their skeletal disease. Owing to the
prolonged course of metastatic bone disease (Coleman and
Rubens, 1987), the frequency of skeletal events in relation to
average patient survival assumes particular importance. Without
bisphosphonate therapy, a major skeletal event occurs on average
once every 3–4 months (Hortobagyi et al, 1996; Theriault et al,
1999). This can seriously diminish a patient’s quality of life, as well
as having huge resource implications for health services (Richards
et al, 1993).
Metastatic bone disease is associated with a disruption of the
normal coupling between bone formation and resorption, typically
resulting in net osteolysis leading to loss of structural integrity and
subsequent skeletal events. Bone-targeted drug therapy, principally
using the bisphosphonates, has been aimed at disruption of this
osteoclast mediated bone resorption. Trials carried out over the
last decade have provided overwhelming evidence supporting the
use of bisphosphonates in reducing the morbidity of metastatic
bone disease from across a range of tumour types (Hortobagyi
et al, 1996; Berenson et al, 2001; Rosen 2002; Saad et al, 2002).
However, despite the overall clinical benefits of bisphosphonates, it
is currently impossible to predict whether an individual patient
will benefit from a bisphosphonate.
Type I collagen is the predominant protein in bone and its
breakdown products are being increasingly investigated as
markers of bone resorption. A number of studies have shown
that collagen breakdown markers are correlated with the presence
of metastatic disease. N-telopeptide (Ntx) is a peptide fragment of
the N-terminus of type I collagen, and is relatively easy to measure.
It appears to be one of the most potentially useful of these markers
in metastatic bone disease (Lipton et al, 2001). In recent years,
clinical studies have demonstrated a correlation between bone
resorption markers, especially Ntx, and the presence and extent of
metastases, prognosis and response to treatment (Lipton et al,
2001). A study by Vinholes et al (1996) showed a significant
correlation between metastatic bone pain and bone resorption.
Several subsequent studies in both breast and prostate cancer
patients have confirmed this initial finding (Jagdev et al, 2001).
Both oral and intravenous bisphosphonate therapy have been
shown to reduce Ntx levels and, importantly, only those patients
who showed normalisation of bone resorption following bispho-
sphonate treatment experienced clinical benefit in terms of an
improvement in pain, analgesic use and morbidity (Vinholes et al,
1997).
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lIn osteoporosis, a clear relationship has been established
between levels of bone markers such as Ntx and the occurrence
of skeletal complications, whether or not a patient has received
bone-specific therapy. However, with few exceptions (Lipton et al,
1998; Menssen et al, 2002), little work has been carried out on the
possible correlation between bone markers and the occurrence of
skeletal events in metastatic bone disease. If such a link can be
firmly established, then it may be appropriate to direct the
management of patients with metastatic bone disease to maintain
or lower an individual’s bone marker values into the normal range.
This study seeks to determine if there is such a relationship
between Ntx levels and subsequent skeletal complications in
patients with metastatic bone disease.
METHODS
Patients
A total of 121 unselected, consecutive patients with histologically
proven malignancy and bone metastases, confirmed by appro-
priate imaging (plain X-ray, CT scan or MRI), were prospectively
studied in the Cancer Research Centre in Sheffield, a regional
referral centre for patients with bone metastases. All patients were
over 18 years of age and had signed informed consent according to
local guidelines with the approval of the appropriate Ethics
Committee. Patients with lytic, sclerotic and mixed lesions as
defined radiologically were included. Patient characteristics are
shown in Table 1.
Measurements of the bone resorption marker Ntx were carried
out in all 121 patients. The date of the first Ntx measurement was
recorded for each patient as the baseline value (month zero).
Further measurements were taken at approximately monthly
intervals. All 121 patients had Ntx measurements available over
at least 3 months or until death if this occurred first. In all, 95
patients were evaluable for at least 6 months. Where possible,
patients were followed up for a maximum of 24 months, but the
number of patients available to the study decreased considerably
over the later months due to progression of disease or return to a
routine clinic outside Sheffield.
In all, 29 patients also had extra-skeletal metastases at baseline,
most commonly affecting the liver, but including lung and lymph
node involvement. All patients in the study received bispho-
sphonate therapy and 93 patients had not received any such
treatment before the first Ntx measurement. Most patients (75)
were treated with oral clodronate (1600mg); other treatments
included IV pamidronate, 90mg (29 patients), IV clodronate,
1500mg (eight patients) and IV zoledronic acid, 4mg (nine
patients). Patients were treated with endocrine or chemotherapy
treatments as clinically indicated.
Ntx measurement
The bone resorption was assessed approximately monthly by
measurement of urinary crosslinks in an early morning, second
voided urine sample, collected on the day of outpatient attendance
and stored at  201C for later analysis. These measurements were
made using a chemiluminescence assay for the Ntx using a Vitros
ECI analyser (Hanson et al, 1992).
The coefficient of variation of the test varies from 6.8 to 14.9%
across the range of 96–1928nmol bone collagen equivalents. The
Ntx normal ranges were based on normal male (71 subjects) and
female controls (58 premenopausal and 92 postmenopausal
subjects) in the regional population, not known to have bone
disease or to be taking drugs known to affect bone metabolism.
None had had recent fractures. The resultant Ntx normal range
used in our centre was: male 16–107nmolmmol
 1 creatinine and
female 10–87nmolmmol
 1 creatinine for premenopausal women
and 32–124nmolmmol
 1 creatinine for postmenopausal women.
A level of 100nmolmmol
 1 creatinine was selected as a reasonable
simple approximation of the upper limit of normal across the
study population.
Skeletal complications
For all patients, any skeletal complications occurring after the
initial Ntx measurement were recorded. Skeletal complications
were defined as radiotherapy to bone, hypercalcaemia (corrected
serum calcium concentration X2.7mmoll
 1), spinal cord or nerve
root compression, symptomatic radiographically confirmed patho-
logical fractures, orthopaedic surgery to bone, hospital admissions
for control of bone pain and/or death due to metastatic bone
disease. It was considered important to include death as a skeletal
complication, as patients with the worst prognosis were more
likely to die early either before or as a consequence of a
particularly catastrophic skeletal event. Routine plain radiographs
were not obtained, therefore excluding the detection of asympto-
matic fractures. As skeletal-related events may be inter-related (e.g.
pathological fracture followed by surgery followed by radio-
therapy), the primary, more conservative analysis took into
account only the first event in any 21-day period. However, the
total number of events, not taking account of the 21-day window,
was also recorded.
Statistical methods
Spearman’s rank correlation coefficients were obtained to assess
whether there were relationships between the baseline Ntx, or the
mean of the Ntx values between 0 and 3 months, and the numbers
of skeletal complications during the subsequent 3 months. These
were also obtained for Ntx at 3 months, or the mean of the Ntx
values between 4 and 6 months, and the numbers of skeletal
complications during months 4–6. w
2 tests of association were
performed on these various Ntx measures, grouped into four
categories, and whether or not a patient had one or more skeletal
complication.
Univariate and multivariate logistic regression models (Armi-
tage and Berry, 1994) were fitted to determine as to whether Ntx
measurements could predict a skeletal event and/or death over
Table 1 Baseline patient characteristics
Tumour
type
Number of
patients
Median age
in years
Median time from cancer
diagnosis to diagnosis of
bone metastasis in
months (range)
Time from diagnosis
of bone metastasis to
baseline Ntx in
months (range)
Number of
patients with metastasis
at other sites
at baseline
Breast 91 55.0 37.0 (0.0, 187.1) 9.9 (0.0, 65.1) 24
Prostate 26 69.5 3.5 (0.0, 96.0)
a 21.5 (4.0, 101.0) 3
Other
b 4 48.0 8.5 (1.0, 206.0) 12.5 (1.0, 19.3) 2
Total 121 56.0 30.5 (0.0, 206.0) 10.4 (0.0, 101.0) 29
aThis apparently low value is because 50% of the prostate cancer patients had bone metastases present at the time of diagnosis of their primary cancer.
bIncludes 1 lung, 1 renal, 1
thyroid and 1 Sertoli cell tumour.
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la 3-month time period. A 3-month time period was considered as
the maximum interval that one might expect a single biochemical
measurement to reflect accurately the underlying metabolic bone
state. In the multivariate analyses, the other factors included in the
models were age, sex and cancer type. Adjusted odds ratios were
presented for each level of Ntx measurements compared with a
reference category. No adjustment was made for multiple testing.
RESULTS
Distribution of skeletal complications and dependence
upon Ntx values
The distribution of the type of skeletal complication over the 0–6-
month time period is shown in Table 2 in relation to the Ntx value
measured in the month before the event occurred. The data are not
mutually exclusive, since several patients had more than one type
of event and eight patients had more than one episode of the same
type of event. Consistent with other studies (LoRusso, 2001), the
most frequent skeletal event was radiotherapy to bone, followed by
fracture or orthopaedic surgery to bone, with spinal cord or nerve
root compression and hypercalcaemia relatively less frequent. For
every type of skeletal complication, the median Ntx value was
substantially above the normal range, for the less common but
extreme events of spinal cord compression and hypercalcaemia, all
Ntx values were above the normal range. Figure 1 shows the mean
(and 95% confidence intervals) for Ntx values at monthly intervals
over 6 months for those patients with and without one or more
skeletal complication. A clear distinction in Ntx values for the two
groups is seen.
Table 3 shows the distribution of the numbers of skeletal
complications occurring during the first (0–3 months) and second
(4–6 month) 3-month time periods. In all, 73 and 38 events were
recorded in the first and second 3-month time periods,
respectively. Overall, there was a total of 111 complications in
the 121 patients over the 6 months. In all, 21 patients (17%) died
during the first 6 months of observation, four before experiencing
a specific skeletal event.
Relaxation of the rule ignoring additional complications
occurring within a 21-day window produced an additional 13
skeletal events. Almost all of these occurred in the first 3 months
(three orthopaedic surgery following fractures, six radiotherapy
after spinal cord compression and four admissions for pain control
after fractures). Since this study was primarily concerned with
relationships to one or more events, the remainder of the analyses
refer to the data with the 21-day window applied.
Analysis of 0–3 month data
Figure 2A presents a scatter plot of Ntx at baseline (using a
logarithmic scale) against the number of skeletal complications
during 0–3 months. While there is evidently a wide scatter of Ntx
values, nevertheless these data show a clear relationship between
the number of complications and the Ntx value. The Spearman
rank correlation coefficient (r) is 0.62 (Po0.001). A similar plot for
the 0–3-month period using the mean Ntx during the first 3
months (derived from the four measurements at baseline and 1, 2
and 3 months) instead of Ntx at baseline was also strongly
correlated with the number of skeletal complications (r¼0.66,
Po0.001). However, the single baseline Ntx is more clinically
useful as it enables prediction for events over the subsequent three
months.
Interpretation of the predictive value of Ntx as a continuous
variable is difficult, and therefore the Ntx values were grouped.
Table 2 Distribution among the various types of skeletal complication
during the 0–6 month period
Skeletal event
and/or death
Number of
events
Median (and range)
of Ntx value
Fracture 19 231 (47–698)
Cord compression 4 232 (140–1762)
Hypercalcaemia 7 273 (146–683)
Radiotherapy 35 164 (26–720)
Admission for pain control 15 193 (45–1412)
Death 21 199 (30–683)
The table shows the median of the Ntx value that was recorded in the month prior
to the event, as well as minimum and maximum values of Ntx for each type of event.
Note that these counts are not mutually exclusive as several patients had more than
one type of event during the time period 0–6 months. The analysis includes the 111
patients who remained on study or died during the first 6 months.
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Figure 1 Mean Ntx values vs time (bars show 95% confidence intervals)
for patients with (–m–) or without (–’–) a skeletal complication over
the period 0–6 months.
Table 3 Distribution of skeletal complications excluding and including death during 0–3 months and 4–6 months
0–3 months 4–6 months
Number of
events
Number of patients excluding
death (including death) %
Number of patients excluding
death (including death) %
Zero 75 (72) 62.0 (59.5) 73 (63) 76.8 (66.3)
One 31 (31) 25.6 (25.6) 20 (26) 21.1 (27.4)
Two 10 (12) 8.3 (9.9) 2 (6) 2.1 (6.3)
Three 5 (6) 4.1 (5.0) 0 (0) 0 (0)
Total number of patients 121 (121) 100 (100) 95 (95) 100 (100)
Total number of complications: 66 (73) (0–3 months), 24 (38) (4–6 months).
Correlation between Ntx and skeletal complications
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 1
creatinine, corresponding approximately to the normal male and
premenopausal female levels; 50–100nmolmol
 1 creatinine,
corresponding closely to the upper normal range for postmeno-
pausal women; 100–200nmolmol
 1 creatinine, defining a group
with moderately accelerated bone resorption; and
4200nmolmol
 1 creatinine, representing very rapid bone resorp-
tion. Table 4A shows the frequency of skeletal complications and
(with the 0–50 group as the normal reference category) both the
unadjusted and adjusted odds ratios with 95% confidence intervals
for a patient to experience a skeletal complication for each of the
four Ntx value groups. There was a strong and highly significant
association between baseline Ntx and the occurrence of a skeletal
complication (Po0.001; test of association). Although the data are
not shown, a significant association between baseline Ntx and the
occurrence of a skeletal complication was also observed (Po0.001)
when death was not included as a complication.
Both univariate and multivariate logistic regression models were
fitted to the data with any skeletal complication as the dependent
variable. With univariate analysis based on the baseline Ntx value,
the model correctly predicted 41 (84%) of the 49 patients who
would experience a skeletal complication over the 3-month period.
In the multivariate analysis, the factors included in the model were
age, sex, cancer type and the categorical values of baseline Ntx.
Again, the model correctly predicted 41 (84%) of the 49 patients
with skeletal complications. The factors age, sex and cancer type
did not significantly affect the chances of a patient having a
skeletal complication (P¼0.80, 0.84 and 0.76, respectively), while
baseline Ntx was highly significant (Po0.001), both in the
unadjusted and the adjusted analyses. Patients with a baseline
Ntx 4100nmolmmol
 1 creatinine (i.e. above the normal range)
were 19.48 (95% CI 7.55, 50.22) times more likely to experience a
complication over the subsequent 3 months than patients with
‘normal’ baseline Ntx values (o100nmolmmol
 1 creatinine).
In all, 28 patients had received bisphosphonate therapy prior to
monitoring of Ntx levels in this study. However, the associations
described above between baseline Ntx and skeletal complications
were very similar when these patients were excluded. The adjusted
odds ratios for the 93 bisphosphonate naı ¨ve patients are shown in
Table 5. Again, baseline Ntx was highly significant (Po0.001), and
the multivariate logistic regression model correctly predicted 28
(80%) of the 35 patients who experienced a skeletal complication
during months 0–3. Age, sex and cancer type did not contribute to
the multivariate model (all P40.15).
Analysis of 4–6 month data
Figure 2B shows the scatter plot for the 3-month Ntx value
(regarded as a new predictor) against the number of skeletal
complications in the subsequent 3-month time period (months 4–
6). The Spearman’s rank correlation coefficient for this analysis
was 0.46 (Po0.001). A similar plot for the data using the mean Ntx
measurements from months 4, 5 and 6, instead of Ntx at 3 months,
also showed a highly significant relationship.
Table 4b shows the frequency of skeletal complications and
(again with the 0–50 group as the normal reference category) the
unadjusted and adjusted odds ratios with 95% confidence intervals
for a patient to experience a skeletal complication during months
4–6 for each of the four Ntx value groups. Once more there was a
statistically significant association between the Ntx value at 3
months and the occurrence of skeletal complications during this
second 3-month time period (Po0.001). As in the initial 3-month
time period, patients with a baseline Ntx4100nmol/mmol
creatinine (ie above the normal range) were at significantly higher
risk of subsequent complications. The univariate and multivariate
logistic regression models correctly predicted 20 (65%) and 18
(58%) of the 31 patients, respectively, who experienced a skeletal
complication during months 4–6. The factors age, sex and cancer
type were not statistically significant in the multivariate logistic
regression model (all P40.3).
Biochemical response and follow-up for longer than 6
months
Although it was not a primary aim of the study, estimates of
response were determined by examining data from patients with a
baseline Ntx450nmolmmol
 1 creatinine and who therefore had
scope for a biochemical response defined as 450% reduction in
Ntx level. Progression was defined as 450% increase and no
change as between 50% reduction and 50% increase (Vinholes et al,
1997). At 3 months, the data show 15 out of 76 (20%) responders,
36 out of 76 (47%) no change and 25 out of 76 (33%) progression.
Response after 3 months, but before 6 months was uncommon,
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Figure 2 Scatter plots of baseline Ntx (log scale) against the number of
skeletal complications during (A) 0–3 months and (B) 4–6 months.
Median values of Ntx in nmolmmol
 1 creatinine were 65.5 (no skeletal
complication), 171 (one skeletal complication), 298.5 (two skeletal
complications) and 240.5 (three skeletal complications) in (A) and 49.0
(no skeletal complication), 142 (one skeletal complication) and 197.5 (two
skeletal complications) in (B).
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loccurring in 4 out of 33 (12%) with 22 out of 33 (67%) showing no
change and seven out 33 (21%) progression. The majority of
patients on the study received oral clodronate and this response
rate is consistent with previous data with this drug. Higher
biochemical response rates would be expected with more potent IV
bisphosphonates (Vinholes et al, 1997; Jagdev et al, 2001). A
proportion of the patients (approximately 21%) had already been
on bisphosphonates prior to study entry and may have already
achieved a biochemical response.
For patients monitored for more than 6 months, the numbers of
patients for whom results were available decreased progressively
from 47 for 7–9 months to three for 22–24 months. There were
relatively few skeletal complications and the majority of patients
had Ntx values in the normal range, reflecting the previous
observation that elevated Ntx is associated with poor prognosis.
(Ali et al, 2000). Although not appropriate for formal statistical
testing, a probable relationship between Ntx and the occurrence of
skeletal events remains. Ntx was 4100nmolmmol
 1 creatinine in
eight out 22 (36%) and 11 out of 82 (13%) of the 3-month periods
of patient observation with and without an event/death, respec-
tively.
DISCUSSION
This study in patients with metastatic bone disease has indicated a
strong, statistically significant correlation between the rate of bone
resorption as measured by Ntx and the frequency of skeletal
complications. We are not aware of any previous studies in
metastatic bone disease that have related Ntx levels to the range of
skeletal complications considered in this study. The baseline Ntx
was a statistically reliable predictor of complications over the first
3 months and the 3-month Ntx value was also a strong predictor of
complications occurring in the following 3 months. This was true
regardless of whether data were limited to patients who were
bisphosphonate naive at study entry, and the strength of the
correlation is particularly striking in view of the fact that all
patients received bisphosphonate therapy after entry to the study.
The multivariate logistic regression model was able to predict
correctly 84% of patients who had one or more events in the 0–3-
month period, based on baseline Ntx. This is sufficiently accurate
to be clinically useful in patient management. For the 4–6-month
period, despite the fact that all patients had been on bispho-
sphonates for at least 3 months, the model was still of predictive
value, although less accurate (58% patients correctly identified).
The beneficial effects of anticancer treatments and bisphosphonate
therapy, as well as the attrition of the worst prognosis patients,
probably explain the lower event rate in the second (4–6 months)
time period.
Overall, bisphosphonates reduce the frequency of skeletal events
by 25–40% (Lipton et al, 2000; Berenson et al, 2001). However,
bisphosphonates are a relatively costly additional intervention in
cancer care, which is now applicable to a very large proportion of
patients with advanced malignancy. The cost effectiveness has
Table 4 Distribution of skeletal complications and unadjusted and adjusted odds ratios according to (A) baseline Ntx range for the 0–3 month time
period and (B) the 3-month value for the 4–6-month time period
(A) baseline Ntx
range for the
0–3 month time period
Baseline Ntx/Ntx value
at 3 months (nmol/mmol
creatinine)
Number of
patients
Number of patients
having any skeletal
complication
% patients having
any skeletal
complication
Unadjusted
odds ratio
95% confidence
interval
Adjusted odds
ratioa
95% confidence
interval
0–50 31 3 9.7 1 * 1 *
450–100 34 5 14.7 1.61 0.35, 7.38 1.51 0.31, 7.45
4100–200 26 16 61.5 14.93 3.58, 62.34 14.24 3.37, 60.17
4200 30 25 83.3 46.67 10.11, 215.42 42.17 9.01, 197.45
Total 121 49 40.5 * * * *
3-month value for the
4–6-month time period
0–50 35 4 11.4 1 * 1 *
450–100 24 7 29.2 3.19 0.82, 12.48 2.12 0.49, 9.20
4100–200 11 6 54.5 9.30 1.92, 45.10 10.44 1.93, 56.45
4200 22 14 63.6 13.56 3.50, 52.63 9.98 2.47, 40.33
Total 92 31 33.7 * * * *
aAdjusted for age, sex and cancer type.
Table 5 Distribution of skeletal complications and adjusted odds ratios according to baseline Ntx range for the 0–3-month period for patients not on
bisphosphonate therapy at the time of baseline Ntx measurement
Baseline Ntx
(nmolmmol
 1 creatinine)
Number of
patients
Number of
patients having any
skeletal complication
% patients having
any skeletal
complication Odds ratio
a
95% confidence
interval
0–50 23 1 4.3 0.37 0.03, 4.67
450–100
b 27 3 11.1 1 *
4100–200 20 12 60.0 16.33 2.78, 95.87
4200 23 19 82.6 38.24 6.01, 243.42
Total 93 35 37.6 * *
aAdjusted for age, sex and cancer type.
bThe 450–100 group was used as the reference category since only one skeletal complication occurred in the Ntx 0–50nmolmmol
 1
creatinine range which gave unstable estimates when this range was used as the reference category.
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lbeen questioned (Hillner, 2001) and prioritisation of bispho-
sphonate use is needed. It is not known whether the relative
benefits of bisphosphonates are the same across the range of
possible bone resorption rates. However, on the assumption that
they are, with about one-third of events prevented, our data
suggest that the numbers of patients who would need to be treated
to prevent one skeletal event would be 31, 17, 3 and 2 for the o50,
50–100, 100–200, and 4200mmolmol
 1 creatinine levels of Ntx,
respectively. A more cost-effective use of bisphosphonates might
be to reserve them until patients have Ntx levels above
100nmolmmol
 1 creatinine and adjust the dose and schedule to
maintain a normal rate of bone resorption.
The current work is consistent with the study by Lipton et al
(1998), which investigated the fracture rate in 21 cancer patients
with bone metastases who received intravenous pamidronate and
whose baseline Ntx levels were above the normal range. In the 12
patients who normalised Ntx, five patients (42%) developed
fractures, whereas in the nine patients who failed to normalise,
eight patients (89%) developed fractures (P¼0.07). When disease
progression was included in the analysis in the above study, the
association with Ntx did reach statistical significance (P¼0.03).
Although these data represent only a small number of patients,
they also suggested that normalisation of bone resorption should
be the goal in reducing fracture rate.
The conclusions of the current study in patients with
metastatic bone disease parallel those from studies of bone
markers in bone loss due to osteoporosis. In one of the most
comprehensive studies, nine bone turnover markers were mea-
sured in 375 women aged between 50 and 85 years (Greenfield et al,
2000), including Ntx and C-telopeptide (Ctx). This study
concluded that high marker levels were associated with an
increased risk of vertebral fracture. There are also many
osteoporosis studies that have demonstrated the role of bone
markers in assessing response to anti-resorptive therapy (Gonnelli
et al, 1997).
Although urinary Ntx has proved to be one of the most
responsive bone markers in metastatic bone disease and results
from the present study are encouraging, it would be desirable to
study the relationship between skeletal events and other urine and
serum bone markers. Serum markers are especially convenient as
blood is often being taken for other purposes (though diurnal
variation is a problem for serum) and serum measurement avoids
complex urine collection and creatinine correction. A recent study
of ibandronate in multiple myeloma (Menssen et al, 2002)
demonstrated that patients experienced significantly fewer skele-
tal-related events per patient year when the ibandronate dose
selected effectively suppressed the bone turnover markers serum
osteocalcin and urinary Ctx. This study also found that patients
experiencing a defined reduction in both bone markers suffered
fewer events than in those with reduction in only one marker,
raising the possibility that an index comprising more than one
bone marker may add further predictive value.
Large, multicentre trials in metastatic bone disease with the
potent bisphosphonate, zoledronic acid have recently been
completed. Using the principles and concepts developed in the
present study, we are currently analysing the marker and skeletal
event data from these trials, to further assess the role of markers in
prediction of skeletal complications and determining its value in
routine clinical practice.
Further work will also be necessary to demonstrate that patients
who normalise their Ntx level following bisphosphonate therapy,
experience fewer skeletal events than those who do not normalise.
Nevertheless, the clear conclusion of the present work that Ntx
levels in the normal range are associated with a much-reduced
incidence of skeletal events, together with corresponding previous
findings for pain and quality of life, provide strong evidence that
normalisation of bone resorption should be a major aim of
therapy. This also adds weight to the argument that bone
resorption measurements should become a routine part of
management of patients with metastatic bone disease.
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